uniQure (NASDAQ:QURE) Hits New 1-Year High After Analyst Upgrade

uniQure (NASDAQ:QURE)’s share price hit a new 52-week high on Monday after Stifel Nicolaus raised their price target on the stock from $12.00 to $32.00. Stifel Nicolaus currently has a buy rating on the stock. uniQure traded as high as $17.63 and last traded at $17.54, with a volume of 1889446 shares changing hands. The stock had previously closed at $15.40.

QURE has been the subject of several other reports. Cantor Fitzgerald raised their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, December 10th. StockNews.com raised uniQure to a “sell” rating in a report on Wednesday, December 11th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. HC Wainwright restated a “buy” rating and set a $25.00 price objective on shares of uniQure in a research note on Tuesday, December 10th. Finally, The Goldman Sachs Group boosted their target price on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average price target of $32.13.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 3,418 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the sale, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 4.74% of the company’s stock.

Institutional Investors Weigh In On uniQure

Large investors have recently added to or reduced their stakes in the stock. RTW Investments LP acquired a new position in uniQure during the 3rd quarter valued at $49,000. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 57.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 3,663 shares during the period. Atria Investments Inc acquired a new position in shares of uniQure in the third quarter valued at $53,000. Quarry LP bought a new position in uniQure in the third quarter worth $58,000. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,306 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

uniQure Trading Up 13.9 %

The business’s 50 day moving average price is $7.04 and its 200-day moving average price is $6.38. The company has a market cap of $854.95 million, a price-to-earnings ratio of -3.36 and a beta of 0.89. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, research analysts forecast that uniQure will post -3.82 EPS for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.